SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Simcha Therapeutics (“Simcha”), a clinical-stage ...
Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...
The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...
Bone morphogenetic proteins (BMPs) are growth factors that regulate the size of intestinal crypts. This study shows that ...
A comprehensive, multi-phase investigation published in Advanced Science suggests that the amino acid tryptophan (Trp) may be a key determinant of therapeutic response to conventional synthetic ...
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on ...
MIT and Harvard reserchers have developed immune-evading CAR-NK cells that eliminate cancer in mice while avoiding cytokine ...
Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.
GLP-1 receptor agonist therapy reduced surgical abscess repairs and hospitalizations among people with hidradenitis ...
Investigators employed the Accelerating Medicines Partnership to identify noninvasive biomarkers of lupus nephritis pathology and treatment response.
EyePoint (EYPT) announced details for its pivotal Phase 3 program evaluating Duravyu for the treatment of diabetic macular edema with first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback